Retatrutide (LY3437943) is an investigational triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. It is currently in Phase 3 clinical trials (TRIUMPH program) for the treatment of obesity, obstructive sleep apnea, and metabolic dysfunction.

Is retatrutide FDA approved?

No, as of 2026, retatrutide has not yet been approved by the FDA or EMA. It is currently undergoing Phase 3 clinical trials focusing on safety and efficacy markers including weight-loss, liver fat reduction, and dysesthesia tracking.

What makes retatrutide different from tirzepatide or semaglutide?

Unlike semaglutide (a single GLP-1 agonist) and tirzepatide (a dual GIP/GLP-1 agonist), retatrutide adds a third mechanism: glucagon receptor agonism. This triple-action approach aims to significantly increase energy expenditure while reducing appetite.

Retatrutide Phase 3 Trial Sleep Quality Improvement Results

Retatrutide phase 3 trial sleep quality improvement results from the TRIUMPH program hold significant promise, especially for obstructive sleep apnea (OSA) endpoints in TRIUMPH-1 and TRIUMPH-2 [1][2]. While full data on apnea-hypopnea index (AHI) reductions, Epworth Sleepiness Scale (ESS) scores, and Functional Outcomes of Sleep Questionnaire (FOSQ) improvements are pending until 2026, TRIUMPH-4's topline results show up to 28.7% weight loss, which may indirectly enhance sleep by alleviating obesity-related breathing issues [1]. This article details the trial designs, key metrics, safety findings, and what to expect next for retatrutide phase 3 trial sleep quality improvement results.

Introduction to Retatrutide Phase 3 Trial Sleep Quality Improvement Results

Retatrutide represents a next-generation approach to tackling obesity and its complications, including poor sleep. As an investigational therapy, it targets multiple hormonal pathways to drive substantial weight loss. The ongoing phase 3 trials are designed to evaluate its broader impacts, with a spotlight on sleep disruptions common in obese populations [1][2].

What is Retatrutide? Triple Agonist Mechanism for Obesity and OSA

Retatrutide (LY3437943) is a triple hormone receptor agonist that activates GIP, GLP-1, and glucagon receptors simultaneously [4]. This unique retatrutide's triple agonist mechanism enhances appetite suppression, increases energy expenditure, and improves blood sugar control more effectively than dual agonists like tirzepatide. In patients with obesity and OSA, excess neck fat narrows airways, causing repeated breathing pauses that fragment sleep and lead to daytime fatigue.

Early phase 2 data showed up to 24.2% weight loss at the highest dose, hinting at potential relief for OSA symptoms [4]. The retatrutide phase 3 trial sleep quality improvement results will test if this translates to measurable sleep gains in larger groups.

Overview of the TRIUMPH Phase 3 Program

Launched in 2023 by Eli Lilly, the TRIUMPH program comprises four multicenter, randomized, double-blind, placebo-controlled trials enrolling over 5,800 adults with obesity or overweight plus comorbidities [5]. Participants receive weekly subcutaneous injections alongside diet and exercise for 52-104 weeks. These registrational studies assess retatrutide across obesity, OSA, knee osteoarthritis (OA), and cardiovascular disease (ClinicalTrials.gov) [1][2][5].

TRIUMPH-1 and TRIUMPH-2 feature "basket" designs with nested substudies for OSA and OA, positioning them as key sources for retatrutide phase 3 trial sleep quality improvement results [2][3].

Why Sleep Quality Matters in Obesity Trials

Obstructive sleep apnea affects up to 70% of people with obesity, creating a vicious cycle of fatigue, weight gain, and health risks like hypertension and diabetes. Poor sleep reduces energy for exercise and healthy eating, undermining weight loss efforts. Measuring sleep quality in trials like TRIUMPH helps gauge holistic benefits beyond the scale.

Retatrutide phase 3 trial sleep quality improvement results could demonstrate if dramatic weight reduction breaks this cycle, offering new hope for non-surgical OSA management.

TRIUMPH Clinical Trial Status and Design

The TRIUMPH trials provide robust data on retatrutide's efficacy and safety in real-world obesity scenarios. Doses escalate from 1 mg to 12 mg weekly, with placebo arms for comparison. As of early 2026, TRIUMPH-4 is complete, while others near full readout (Eli Lilly Investor News) [1].

The Four TRIUMPH Trials: TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, and TRIUMPH-4

TRIUMPH-1 and TRIUMPH-2: Basket trials for broad weight management, including GSA1 (OSA) and GOA1 (OA) protocols. These directly evaluate retatrutide phase 3 trial sleep quality improvement results via week 80 assessments [2][3].
TRIUMPH-3: Focuses on participants with established cardiovascular disease, prioritizing long-term metabolic and heart health outcomes [1].
TRIUMPH-4: Dedicated to knee OA in obese patients, with topline results released December 2025 confirming superior efficacy [1].

This structure allows cross-trial comparisons for comprehensive insights.

Participant Enrollment and Study Duration

Enrollment exceeded 5,800 diverse adults, with BMIs typically over 30 kg/m² and comorbidities like OSA in 20-30% of cohorts [5]. Core treatment phases last 68-89 weeks, followed by optional 24-week extensions for maintenance data [1][2]. High adherence rates ensure reliable long-term findings on sustained weight loss and sleep improvements.

Primary and Secondary Endpoints Across Trials

Primaries include percent weight change (obesity), AHI change (OSA), and WOMAC pain scores (OA) [2][3]. Secondaries cover ESS for sleepiness, FOSQ for functional sleep outcomes, cardiovascular biomarkers, and quality-of-life measures [2][3]. Polysomnography confirms OSA endpoints objectively.

Sleep Quality Improvement Endpoints in Retatrutide Phase 3 Trials

Sleep assessments in retatrutide phase 3 trials center on OSA as a proxy for quality, given its prevalence in obesity. Endpoints use validated tools to capture both objective breathing events and subjective daily impacts. Data from TRIUMPH-1/2 will reveal the full scope [2][3].

Obstructive Sleep Apnea (OSA) Focus in TRIUMPH-1 and TRIUMPH-2

These trials embed GSA1 subsets with moderate-to-severe OSA (AHI 15-100 events/hour) [2][3]. Retatrutide's weight loss is hypothesized to enlarge airways and stabilize breathing. No interim results yet, but design mirrors successful phase 2 trends [4].

Key Metrics: AHI Reduction, ESS, and FOSQ Scores

Apnea-Hypopnea Index (AHI): Counts breathing pauses per sleep hour; primary is percent reduction from baseline to week 80. Success thresholds: ≥50% drop or AHI <5 (normal) or 5-14 with minimal symptoms [2][3].
Epworth Sleepiness Scale (ESS): 8-question survey scoring daytime drowsiness (0-24); target ≤10 indicates low risk [2][3].
Functional Outcomes of Sleep Questionnaire (FOSQ): 30-item tool evaluating vigilance, activity, and social function via win-ratio analysis (ClinicalTrials.gov NCT05929066) [2][3].

These metrics provide a complete picture of retatrutide phase 3 trial sleep quality improvement results.

Current Availability of Phase 3 Sleep Quality Data

No topline OSA data as of April 2026; focus has been TRIUMPH-4 [1]. Phase 2 extrapolations suggest 20-30% AHI reductions with similar weight loss, but phase 3 scales this up [4].

Efficacy Results from Completed Trials and Implications for Sleep

TRIUMPH-4's results set a high bar, with weight loss surpassing expectations. This indirectly supports sleep benefits, as studies show 10% weight drop cuts AHI by 25-30%. Retatrutide phase 3 trial sleep quality improvement results from OSA trials may exceed this [1][4].

TRIUMPH-4 Topline Results: Weight Loss and OA Pain Reduction

Over 68 weeks:

12 mg: 28.7% mean loss (71.2 lbs), 26.6% placebo-adjusted [1].
9 mg: Similar trends in pain and function [1].
OA pain: 75-76% reduction (4.5 WOMAC points); 12-15% pain-free vs. 4% placebo [1].

Explore TRIUMPH-4 topline results showing 28.7% weight loss and TRIUMPH osteoarthritis weight loss mechanism.

How Weight Loss May Indirectly Improve Sleep Quality

Reducing visceral and neck fat directly widens airways, lowering AHI. Glucagon activation boosts metabolism, potentially enhancing sleep architecture. Improved OA mobility promotes better sleep positions and routines.

Hypothetical patient: A 250-lb man with OSA might drop 70 lbs, halving AHI and boosting FOSQ scores for renewed energy.

Phase 2 Insights and Expectations for Phase 3 OSA Data

Phase 2 achieved 17-24% loss at 48 weeks, with metabolic gains but no formal OSA measures [4]. Phase 3's longer duration and OSA focus predict stronger retatrutide phase 3 trial sleep quality improvement results, potentially 40-60% AHI responders vs. 20-30% for semaglutide.

Safety Data and Side Effects in Retatrutide Phase 3 Trials

Retatrutide's profile aligns with incretin mimetics: mostly mild, transient GI effects. Dose-dependent risks emerge at 12 mg, but no severe signals like pancreatitis [1].

Discontinuation Rates and Adverse Events

TRIUMPH-4 (BMI ≥35 subgroup):

9 mg: 8.8% AE-related dropouts vs. 4.8% placebo [1].
12 mg: 12.1% [1].

Common AEs: nausea (dose-escalation related). Check strategies to manage retatrutide dysesthesia.

Emerging Dysesthesia Signal in TRIUMPH-4

New in phase 3: dysesthesia (tingling/abnormal touch), not seen in phase 2 [1]. Likely dose-related; clinical relevance under review per dysesthesia risks at 12mg doses. Mitigation includes slower titration.